Ultrashort Antimicrobial Peptide-Antibiotic Conjugate: A New Weapon Against Resistance

What the researchers found

Novel conjugate combining an ultrashort antimicrobial peptide with levofloxacin showed enhanced antibacterial activity against resistant strains through dual-mechanism killing.

Why it matters

Relevant to the expanding applications of peptide-based therapies in medicine.

The numbers in context

Five-amino-acid peptide (UP5) with alternating arginine and biphenylalanine units conjugated to levofloxacin. Tested against multidrug and levofloxacin-resistant isolates.

How the study worked

Study methodology detailed in the full publication.

Who was studied

In vitro testing against multidrug-resistant and levofloxacin-resistant bacterial isolates

What this study cannot tell us

Limitations discussed in the full publication.

How to read the evidence

Evidence level based on study design.

When this study was published

Published in 2025.

The bigger picture

Contributes to the growing body of evidence for peptide therapeutics across medical specialties.

Questions still open

• What are the long-term implications?
• How do results compare to existing evidence?
• What research is needed next?

Common questions

Read the original research

Development of a novel ultrashort antimicrobial peptide-levofloxacin conjugate with enhanced synergistic activity against multidrug and levofloxacin-resistant bacterial isolates.

Research in pharmaceutical sciences, 20(6), 777-788

Citation

Almaaytah, Ammar; Alrashdan, Aseel; Sabi, Salsabeel H. (2025). Development of a novel ultrashort antimicrobial peptide-levofloxacin conjugate with enhanced synergistic activity against multidrug and levofloxacin-resistant bacterial isolates.. Research in pharmaceutical sciences, 20(6), 777-788. https://doi.org/10.4103/RPS.RPS_178_24